Abstract
No public abstract is available from the verified source records.
Éric François, Olivier Guérin, Philippe Follana, Ludovic Evesque, Thomas Aparicio
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cancer statistics, 2010
10.3322/caac.20073 · 2010
Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s
10.1016/j.ejca.2007.12.015 · 2008
Prevalence of patients with colorectal cancer requiring follow-up or active treatment
10.1016/j.ejca.2009.01.012 · 2009
Epidemiology and prognosis of synchronous colorectal cancers
10.1002/bjs.6382 · 2008
Management and survival of colorectal cancer in the elderly in population-based studies
10.1016/j.ejca.2007.08.008 · 2007
Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results
10.1200/jco.2007.25.18_suppl.4069 · 2007
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
10.1016/s0140-6736(07)61086-1 · 2007
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
10.1016/s0140-6736(07)61087-3 · 2007
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1093/annonc/mdh344 · 2004
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administrated bimonthly in elderly patients with colorectal cancer
10.1200/jco.2006.06.9039 · 2006
10.1016/s1040-8428(08)70044-1
10.1016/s1040-8428(08)70044-1
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
10.1038/sj.bjc.6601310 · 2003
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a phase II study
10.1007/s00280-008-0681-2 · 2008
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors
10.1177/107327480701400312 · 2007
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
10.1126/science.1104819 · 2005
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
10.1056/nejmoa032691 · 2004
Unresolved referenced work
Kept as external metadata until matched
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
10.1200/jco.2007.14.9930 · 2008
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
10.1200/jco.2006.09.6305 · 2007
Addition of bevacizumab to bolus flurouracil and leucovorin in first-line metastatic colorectal cancer: results of randomized phase II trial
10.1200/jco.2005.05.112 · 2005
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials
10.1200/jco.2008.17.7931 · 2009
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer
10.1016/s0140-6736(00)02528-9 · 2000
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies
10.1007/s00432-009-0712-3 · 2010
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
10.1093/annonc/mdp233 · 2009
Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BEAT observational cohort study
10.1016/s1359-6349(09)71183-8 · 2009
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study
10.1634/theoncologist.2009-0071 · 2009
10.1200/jco.2008.26.15_suppl.4026
10.1200/jco.2008.26.15_suppl.4026
Unresolved referenced work
Kept as external metadata until matched
A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer
10.1016/j.critrevonc.2008.10.012 · 2009
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
10.1038/sj.bjc.6605663 · 2010
Phase II study of bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer
10.1200/jco.2009.27.15_suppl.e15074 · 2009
Unresolved referenced work
Kept as external metadata until matched
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidynes in first-line treatment of metastatic colorectal cancer: results from the BICC-C study
10.1200/jco.2007.11.3357 · 2007
Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer
10.1200/jco.2009.21.9220 · 2009
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials
10.3109/02841860903524396 · 2010
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
10.1093/jnci/djm086 · 2007
Bevacizumab related adverse events among various age groups of elderly patients with advanced colorectal cancer
10.1200/jco.2007.25.18_suppl.14546 · 2007
Hemostatic complications of angiogenesis inhibitors in cancer patients
10.1002/ajh.21277 · 2008
FOLFOX in patients aged between 76 and 80years with metastatic colorectal cancer
10.1002/cncr.23091 · 2007
Age and adjuvant chemotherapy use after surgery for stage III colon cancer
10.1093/jnci/93.11.850 · 2001
No additional external references are available.